Market closedNon-fractional
IceCure Medical/ICCM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About IceCure Medical
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
Ticker
ICCM
Sector
Healthcare
Trading on
NASDAQ
Industry
Health Care Equipment and Supplies
Headquarters
Caesarea, Israel
Employees
74
Website
www.icecure-medical.com
IceCure Medical Metrics
BasicAdvanced
$38M
Market cap
-
P/E ratio
-$0.32
EPS
2.90
Beta
-
Dividend rate
Price and volume
Market cap
$38M
Beta
2.9
Financial strength
Current ratio
3.392
Quick ratio
2.71
Long term debt to equity
2.681
Total debt to equity
4.718
Management effectiveness
Return on assets (TTM)
-44.46%
Return on equity (TTM)
-86.15%
Valuation
Price to revenue (TTM)
11.26
Price to book
3.29
Price to tangible book (TTM)
3.29
Price to free cash flow (TTM)
-2.893
Growth
Revenue change (TTM)
7.02%
Earnings per share change (TTM)
-24.05%
3-year revenue growth (CAGR)
-9.33%
3-year earnings per share growth (CAGR)
10.84%
What the Analysts think about IceCure Medical
Analyst Ratings
Majority rating from 4 analysts.
IceCure Medical Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$700K
-41.67%
Net income
-$3.6M
24.14%
Profit margin
-514.28%
112.81%
IceCure Medical Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.08
-$0.09
-$0.07
-$0.08
-
Expected
-$0.09
-$0.09
-$0.07
-$0.08
-$0.07
Surprise
-7.69%
-3.33%
-7.14%
0.00%
-
IceCure Medical News
AllArticlesVideos
99.74% Recurrence Free Rate for Women with Breast Cancer Treated with IceCure's ProSense® Cryoablation System: Key Findings Delivered at 32nd Annual Meeting of the Japanese Breast Cancer Society
PRNewsWire·5 days ago
IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification
PRNewsWire·1 week ago
European Study Provides More Evidence Supporting IceCure's ProSense® is Safe & Effective Cryoablation Treatment for Metastatic and Recurrent Breast Cancer
PRNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for IceCure Medical stock?
IceCure Medical (ICCM) has a market cap of $38M as of July 27, 2024.
What is the P/E ratio for IceCure Medical stock?
The price to earnings (P/E) ratio for IceCure Medical (ICCM) stock is 0 as of July 27, 2024.
Does IceCure Medical stock pay dividends?
No, IceCure Medical (ICCM) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next IceCure Medical dividend payment date?
IceCure Medical (ICCM) stock does not pay dividends to its shareholders.
What is the beta indicator for IceCure Medical?
IceCure Medical (ICCM) has a beta rating of 2.9. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell IceCure Medical stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.